Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 3.01, 7.01, 9.01 · 8-K

Palatin Technologies, Inc.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing · Regulation FD Disclosure

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On May 18, 2026, Palatin Technologies, Inc. (the “Company”), acting pursuant to authorization from its Board of Directors, provided notice to the NYSE American LLC (the “NYSE”) that it intends to voluntarily withdraw the listing of its common stock, par value $0.01 per share (the “common…

Filed May 18, 2026Accepted May 18, 2026, 5:07 PM EDTCIK 911216Accession 0001493152-26-024219
Share

Company context

We are a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor systems. Our product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.

Current securities

Historical securities (5)

Recent company filings

  1. 10-Q filingNov 16, 2026
  2. 10-K filingSep 28, 2026
  3. SCHEDULE 13G/A - filed by AuGC Partners LLC regarding PALATIN TECHNOLOGIES INCAug 14, 2026
  4. Submission of Matters to a Vote of Security HoldersAug 3, 2026
  5. DEF 14A filingJun 25, 2026

Registered securities in this filing

PALATIN TECHNOLOGIES, INC. · 8-K · Filed 2026-05-18

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, par value $0.01 per share

Symbol
PTN
Exchange
NYSE
Classification
COMMON
Filing context

Context: AsOf2026-05-18

Dimensions: Not supplied

Accession 000149315226024219 · 1 registered-security cover member

Read the exact SEC filing ↗

Disclosure sections

Items 3.01, 7.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 3.01Item 3.01 - Notice of Delisting
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On May 18, 2026, Palatin Technologies, Inc. (the “Company”), acting pursuant to authorization from its Board of Directors, provided notice to the NYSE American LLC (the “NYSE”) that it intends to voluntarily withdraw the listing of its common stock, par value $0.01 per share (the “common stock”), from the NYSE and transfer the listing of its common stock to the Nasdaq Capital Market (the “Nasdaq”). The Nasdaq has approved such listing. The Company expects the listing and trading of its common stock on the NYSE to cease at the close of trading on May 28, 2026. The Company expects the common stock to begin trading on the Nasdaq on May 29, 2026. The common stock will continue to trade under the symbol “PTN”.
Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. The Company issued a press release on May 18, 2026 announcing the transfer of the listing of its common stock from the NYSE to Nasdaq. The press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information in Item 7.01, including Exhibit 99.1, of this Current Report on Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such a filing.
Filed exhibits (1)
EX-99.1 (by filename) ex99-1.htm

EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Palatin to Begin Trading on Nasdaq Stock Exchange PRINCETON, NJ - May 18, 2026 /PRNewswire/ - Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development of novel therapeutics targeting the melanocortin receptor system, today announced that its common stock has been approved for listing on the Nasdaq Capital Market and that the Company will transfer its stock exchange listing to Nasdaq from the NYSE American. The Company expects to begin trading as a Nasdaq-listed company on May 29, 2026, and will continue to trade under the symbol “PTN.” Palatin’s common stock will continue to trade on the NYSE American until the market close on May 28, 2026. “We are pleased to announce our listing on the Nasdaq Capital Market and to join a community of leading biotechnology companies,” said Carl Spana, Ph. D., President and Chief Executive Officer of Palatin Technologies. “We believe the move to Nasdaq will improve the visibility of our common stock, enhance trading liquidity in our shares, and provide us with greater exposure to institutional investors.” Palatin is advancing selective MC4…

Open exhibit ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.